---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287057957.md"
description: "Roivant Sciences shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results."
datetime: "2026-05-20T11:30:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287057957.md)
  - [en](https://longbridge.com/en/news/287057957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287057957.md)
---

# 

Roivant Sciences shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.68, Implies 30% Upside](https://longbridge.com/en/news/287126493.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)